Current Liabilities decreased faster than Amgen Inc 's Cash & cash equivalent, this led to improvement in Amgen Inc 's Quick Ratio to 1.11, Quick Ratio remained below Amgen Inc average.

Within Biotechnology & Pharmaceuticals industry 111 other companies have achieved higher Quick Ratio than Amgen Inc in third quarter 2026. While Quick Ratio total ranking has improved so far during the Q3 2026 to 2719, from total ranking in the second quarter 2026 at 3652.

Explain Quick Ratio?
How much Cash & cash equivalents AMGN�s has?
What are AMGN�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/AMGN/financial-strength

https://api.csimarket.com/api/v1/companies/AMGN/fundamentals

https://api.csimarket.com/api/v1/companies/AMGN/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

AMGN Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	6.61 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	173.28 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	1.11	Subscribe	Subscribe	Subscribe	Subscribe
AMGN's Total Ranking	# 2719	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	-8.91 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	-5.81 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 112
Healthcare Sector	# 608
Overall Market	# 1885

Quick Ratio Statistics
High	Average	Low
5.05	2.07	0.36
(Sep 30 2017)		(Dec 31 2025)

Financial Statements
Amgen Inc 's Current Liabilities	$ 23,231 Millions	Visit AMGN's Balance sheet
Amgen Inc 's Cash & cash equivalent	$ 25,811 Millions	Visit AMGN's Balance sheet
Source of AMGN's Sales		Visit AMGN's Sales by Geography

Cumulative Amgen Inc 's Quick Ratio

AMGN's Quick Ratio for the trailling 12 Months

AMGN Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	12.22 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	94.43 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	0.75	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 2181	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	1.47 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	28.21 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to AMGN Financial Strength Comparisons >> Go to Compare AMGN Quick Ratio to its Competitors

On the trailing twelve months basis AMGN Cash & cash equivalent more than doubled by 173.28 % in Q3 2026 year on year, faster than Current Liabilities, this led to increase in in Amgen Inc 's Quick Ratio to 0.75, Quick Ratio remained below AMGN average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 142 other companies have achieved higher Quick Ratio than Amgen Inc . While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending second quarter 2026 at 4053.

Explain Quick Ratio?
How much Cash & cash equivalents AMGN�s has?
What are AMGN�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Biotechnology & Pharmaceuticals Industry	# 143
Healthcare Sector	# 903
Within the Market	#

trailing twelve months Quick Ratio Statistics
High	Average	Low
2.86	1.01	0.29
(Mar 31 2015)		(Mar 31 2017)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Biotechnology & Pharmaceuticals Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Adaptive Biotechnologies Corporation	3.02	$ 298.954 Millions	$ 98.967 Millions
Atyr Pharma Inc	2.96	$ 48.751 Millions	$ 16.463 Millions
Precision Biosciences Inc	2.90	$ 81.846 Millions	$ 28.258 Millions
Immunitybio inc	2.86	$ 334.329 Millions	$ 116.795 Millions
Editas Medicine Inc	2.66	$ 190.198 Millions	$ 71.582 Millions
Humacyte Inc	2.61	$ 64.523 Millions	$ 24.761 Millions
Autolus Therapeutics Plc	2.52	$ 248.377 Millions	$ 98.647 Millions
Vericel Corporation	2.44	$ 133.493 Millions	$ 54.719 Millions
Adma Biologics Inc	2.25	$ 124.555 Millions	$ 55.475 Millions
Cullinan Therapeutics Inc	2.20	$ 88.260 Millions	$ 40.130 Millions
Exelixis Inc	2.17	$ 892.018 Millions	$ 411.877 Millions
Halozyme Therapeutics Inc	2.12	$ 1,074.480 Millions	$ 506.173 Millions
Relay Therapeutics Inc	2.10	$ 124.184 Millions	$ 59.154 Millions
Biocryst Pharmaceuticals Inc	1.92	$ 375.334 Millions	$ 195.830 Millions
Novavax inc	1.89	$ 622.363 Millions	$ 329.845 Millions
Elutia Inc	1.81	$ 29.093 Millions	$ 16.030 Millions
Lenz Therapeutics Inc	1.78	$ 31.610 Millions	$ 17.750 Millions
Acumen Pharmaceuticals Inc	1.74	$ 78.604 Millions	$ 45.087 Millions
Sana Biotechnology Inc	1.63	$ 121.728 Millions	$ 74.880 Millions
Aligos Therapeutics Inc	1.59	$ 31.094 Millions	$ 19.600 Millions
Atara Biotherapeutics Inc	1.51	$ 9.917 Millions	$ 6.568 Millions
Tarsus Pharmaceuticals Inc	1.36	$ 309.612 Millions	$ 227.114 Millions
Metagenomi Therapeutics Inc	1.12	$ 36.107 Millions	$ 32.340 Millions
Amgen Inc	1.11	$ 25,811.000 Millions	$ 23,231.000 Millions
Coherus Oncology inc	1.11	$ 83.629 Millions	$ 75.636 Millions
Sab Biotherapeutics Inc	0.98	$ 14.438 Millions	$ 14.798 Millions
Passage Bio Inc	0.97	$ 20.160 Millions	$ 20.743 Millions
Bio techne Corp	0.97	$ 350.036 Millions	$ 361.269 Millions
C4 Therapeutics Inc	0.81	$ 33.492 Millions	$ 41.460 Millions
Allogene Therapeutics Inc	0.76	$ 29.270 Millions	$ 38.498 Millions

Date modified: 2026-11-10T11:46:15+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.